Synthesis, Isolation, Characterization and Suppression of Impurities during Optimization of Empagliflozin (Jardiance)-Reference-Cited by-同舟云学术

Synthesis, Isolation, Characterization and Suppression of Impurities during Optimization of Empagliflozin (Jardiance)

Published:2022-02-23 Issue:3 Volume:54 Page:203-219
ISSN:0030-4948
Container-title:Organic Preparations and Procedures International
language:en
Short-container-title:Organic Preparations and Procedures International

Author:

Peng Peng¹,Zhao Chuanmeng²,Yang Jiangtao²,Liu Xiao³,Yu Jun²,Zhang Fuli²

Affiliation:

1. Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Xiacheng, Hangzhou, China

2. Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Pudong, Shanghai, China

3. College of Chemistry and Chemical Engineering, Shanghai University of Engineering Science, Shanghai, China

Funder

China State Institute of Pharmaceutical Industry

Publisher

Informa UK Limited

Subject

Organic Chemistry

Link

https://www.tandfonline.com/doi/pdf/10.1080/00304948.2021.2022922

Reference21 articles.

1. Genotoxic Impurities in Pharmaceutical Manufacturing: Sources, Regulations, and Mitigation

2. SGLT2 inhibitors in the treatment of type 2 diabetes

3. Drug–Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose-Lowering Agents for the Management of Type 2 Diabetes Mellitus

4. Empagliflozin: A sodium–glucose cotransporter 2 inhibitor for treatment of type 2 diabetes

5. The U.S. Food and Drug Administration. FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes. Online at https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm531517.htm. Jardiance was studied in a postmarket clinical trial of more than 7,000 patients with type 2 diabetes and cardiovascular disease. In the trial, Jardiance was shown to reduce the risk of cardiovascular death compared to a placebo when added to standard of care therapies for diabetes and atherosclerotic cardiovascular disease.